-+ 0.00%
-+ 0.00%
-+ 0.00%

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

Barchart·08/11/2026 07:15:00
Listen to the news

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.